Casadei-Gardini et al. showed a lower response to sorafenib in HCC patients undergoing chronic therapy with metformin for T2DM in respect with non-diabetic patients or those taking insulin [5], and suggested an involvement of SIRT-3 in the mechanism of resistance to sorafenib in this setting of patients [4]. Here, INS is linked to hepatocellular carcinoma.